A device developed by MGH investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology
A device developed by Massachusetts General Hospital investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology. In their report appearing in PNAS Early Edition, the researchers describe a smartphone-based device that uses the kind of technology used to make holograms to collect detailed microscopic images for digital analysis of the molecular composition of cells and tissues.
“The global burden of cancer, limited access to prompt pathology services in many regions and emerging cell profiling technologies increase the need for low-cost, portable and rapid diagnostic approaches that can be delivered at the point of care,” says Cesar Castro, MD, of the MGH Cancer Center and Center for Systems Biology, co-lead author of the report. “The emerging genomic and biological data for various cancers, which can be essential to choosing the most appropriate therapy, supports the need for molecular profiling strategies that are more accessible to providers, clinical investigators and patients; and we believe the platform we have developed provides essential features at an extraordinary low cost.”
The device the team has developed – called the D3 (digital diffraction diagnosis) system – features an imaging module with a battery-powered LED light clipped onto a standard smartphone that records high-resolution imaging data with its camera. With a much greater field of view than traditional microscopy, the D3 system is capable of recording data on more than 100,000 cells from a blood or tissue sample in a single image. The data can then be transmitted for analysis to a remote graphic-processing server via a secure, encrypted cloud service, and the results rapidly returned to the point of care.
For molecular analysis of tumors, a sample of blood or tissue is labeled with microbeads that bind to known cancer-related molecules and loaded into the D3 imaging module. After the image is recorded and data transmitted to the server, the presence of specific molecules is detected by analyzing the diffraction patterns generated by the microbeads. The use of variously sized or coated beads may offer unique diffraction signatures to facilitate detection. A numerical algorithm developed by the research team for the D3 platform is capable of distinguishing cells from beads and of analyzing as much as 10 MB of data in less than nine hundredths of a second.
A pilot test of the system with cancer cell lines detected the presence of tumor proteins with an accuracy matching that of the current gold standard for molecular profiling, and the larger field of view enabled simultaneous analysis of more than 100,000 cells at a time. The investigators then conducted analysis of cervical biopsy samples from 25 women with abnormal PAP smears – samples collected along with those used for clinical diagnosis – using microbeads tagged with antibodies against three published markers of cervical cancer. Based on the number of antibody-tagged microbeads binding to cells, D3 analysis promptly and reliably categorized biopsy samples as high-risk, low-risk or benign, with results matching those of conventional pathologic analysis.
The Latest on: Molecular tumor diagnosis
via Google News
The Latest on: Molecular tumor diagnosis
- Kiser: Raising standards for cancer careon November 13, 2020 at 8:00 pm
In Southwest Virginia and around the country, no disease is harder on patients and their families than cancer. Receiving the proper care should not make matters worse.
- Latest Business Report on Colorectal Cancer Therapeutics Market by Emerging Trends, Share, Growth Rate, Opportunities And Market Forecast To 2024on November 12, 2020 at 2:09 am
Global Colorectal Cancer Therapeutics market is expected to grow at significant CAGR over the forecast period. The global Colorectal Cancer Therapeutics is segmented by treatment into by Chemotherapy, ...
- Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cellson November 9, 2020 at 5:05 am
Biocept, Inc., a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, ...
- Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be used as a Companion Diagnostic for LYNPARZA®on November 9, 2020 at 4:05 am
Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic for LYNPARZA® ...
- Stella Diagnostics CEO Joe Abdo featured on Global Cancer Advocacy Podcast ‘Out of Patients with Matthew Zachary’on November 5, 2020 at 6:05 am
In this episode, Dr. Abdo discusses the current state of precision medicine, molecular diagnostic testing for cancer and his experience working in the world of oncology as a two-time young adult ...
- Amid COVID-19 Pandemic, the China Molecular Diagnostics Market is Forecast to Reach US$ 6.3 Billion by 2026on November 4, 2020 at 3:01 am
The "China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease ...
- North America Molecular Cytogenetics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2025on November 4, 2020 at 2:35 am
Molecular Cytogenetics Market is valued at USD 1.89 Billion in 2019 and expected to reach USD 3.84 Billion by 2026 with ...
- CSMC inaugurates molecular labon October 31, 2020 at 5:07 pm
Some of these tests include molecular testing for the translocation of certain tumors, as the diagnostic trend is identifying mutations in the tumor to be definite in diagnosis. Identification of ...
- Cerebrospinal fluid as liquid biopsy for characterizing and policing of medulloblastomaon October 27, 2020 at 3:04 am
While the genomic characterization of medulloblastoma promises a more precise molecular diagnosis, accessing tumor tissue -due to the very nature of its location- is complex and can suppose high ...
- Molecular Diagnostics Devices and Equipment Market Technology Advancements and Demand 2020 to 2030on October 21, 2020 at 7:05 pm
source=releasewire&Mode=07 The regulatory process involving approval of molecular diagnostic tests is often ... By Application: Cancer, Pharmacogenomics, Genetic testing, Infectious disease ...
via Bing News